ORCID as entered in ROS
https://orcid.org/0000-0002-8844-6132
Select Publications
By Dr Kevin Ni
Conference Abstracts
, 2022, 'Isolation of exosomal microRNA to serve as a diagnostic biomarker for prostate cancer: A provisional analysis of 12 patients', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 140 - 140, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200227&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4754
, 2017, 'Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models', in Annals of Oncology, Vol. 28, pp. x78 - x79, http://dx.doi.org/10.1093/annonc/mdx662.006
, 2015, 'Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Cairns, Vol. 116, pp. 33 - 34, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Cairns, Vol. 116, pp. 31 - 31, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2001
, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro.', in CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro., presented at AACR 2014
, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., presented at The St George & Sutherland Medical Research Symposium
, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., presented at LOWY cancer symposium
, 2012, 'Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy.', in Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy., presented at 13th Australasian Prostate Cancer Conference
Filter by type
https://orcid.org/0000-0002-8844-6132